Skip to main content
SpringerLink
Log in

Thrombotic thrombocytopenic purpura related to severe ADAMTS13 deficiency in children

  • Review
  • Published:
Pediatric Nephrology Aims and scope Submit manuscript

Abstract

Thrombotic thrombocytopenic purpura (TTP) related to a severely deficient activity of the von Willebrand factor cleaving protease, ADAMTS (A Disintegrin And Metalloprotease with ThromboSpondin type 1 repeats) 13, is a life-threatening event, the onset of which may occur as early as childhood. TTP is either inherited (Upshaw-Schulman syndrome) via ADAMTS13 gene mutations (neonatal onset) or acquired via anti-ADAMTS13 autoantibodies (childhood onset). TTP is due to platelet- and von-Willebrand-factor-rich thrombi of the microvasculature, inducing mechanical hemolytic anemia, consumption thrombocytopenia, and multivisceral ischemia. Clinical course consists of relapsing acute events triggered mostly by infections, associated icterus and hyperbilirubinemia, severe hemolytic anemia with schistocytosis and a negative Coombs test, severe thrombocytopenia, and sometimes symptoms related to visceral ischemia (renal failure, central nervous system vascular events, other organ failure). The recently available ADAMTS13 laboratory investigation combining measurement of ADAMTS13 activity in plasma, search for an ADAMTS13 circulating inhibitor, and anti-ADAMTS13 IgG and ADAMTS13 gene sequencing is a crucial addition to TTP diagnosis. Plasma exchanges are first-line treatment of acquired TTP, combined with steroids and immunosuppressive drugs. Curative treatment of acute events in Upshaw-Schulman syndrome relies on plasma infusions (provider of active ADAMTS13). Guidelines for preventive treatment of relapses are not clearly established but should associate plasmatherapy and caution to triggers of relapses. Therapeutic perspectives are focused on the development of concentrated plasma-derived ADAMTS13 or recombinant ADAMTS13.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Moake JL (2002) Thrombotic microangiopathies. N Engl J Med 347:589–600

    CAS  PubMed  Google Scholar 

  2. Furlan M, Robles R, Lamie B (1996) Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis. Blood 87:4223–4234

    CAS  PubMed  Google Scholar 

  3. Tsai HM (1996) Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion. Blood 87:4235–4244

    CAS  PubMed  Google Scholar 

  4. Furlan M, Robles R, Galbusera M, Remuzzi G, Kyrle PA, Brenner B, Krause M, Scharrer I, Aumann V, Mittler U, Solenthaler M, Lammle B (1998) Von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med 339:1578–1584

    CAS  PubMed  Google Scholar 

  5. Tsai HM, Lian EC (1998) Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 339:1585–1594

    CAS  PubMed  PubMed Central  Google Scholar 

  6. Noris M, Remuzzi G (2005) Hemolytic uremic syndrome. J Am Soc Nephrol 16:1035–1050

    Article  CAS  PubMed  Google Scholar 

  7. Tsai HM (2006) The molecular biology of thrombotic microangiopathy. Kidney Int 70:16–23

    CAS  PubMed  PubMed Central  Google Scholar 

  8. Caprioli J, Noris M, Brioschi S, Pianetti G, Castelletti F, Bettinaglio P, Mele C, Bresin E, Cassis L, Gamba S, Porrati F, Bucchioni S, Monteferrante G, Fang CJ, Liszewski MK, Kavanagh D, Atkinson JP, Remuzzi G (2006) Genetics of HUS: the impact of MCP, CFH and IF mutations on clinical presentation, response to treatment, and outcome. Blood 108:1267–1279

    CAS  PubMed  PubMed Central  Google Scholar 

  9. Sellier-Leclerc AL, Fremeaux-Bacchi V, Dragon-Durey MA, Macher MA, Niaudet P, Guest G, Boudailliez B, Bouissou F, Deschênes G, Gie S, Tsimaratos M, Fischbach M, Morin D, Nivet H, Alberti C, Loirat C (2007) Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome. J Am Soc Nephrol 18:2392–2400

    CAS  PubMed  Google Scholar 

  10. Kavanagh D, Richards A, Atkinson JP (2008) Complement regulatory genes and hemolytic uremic syndromes. Annu Rev Med 59:293–309

    CAS  PubMed  Google Scholar 

  11. Sadler JE (2005) von Willebrand factor: two sides of a coin. J Thromb Haemost 3:1702–1709

    CAS  PubMed  Google Scholar 

  12. Moake JL, Rudy CK, Troll JH, Weinstein MJ, Colannino NM, Azocar J, Seder RH, Hong SL, Deykin D (1982) Unusually large plasma factor VIII:von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura. N Engl J Med 307:1432–1435

    CAS  PubMed  Google Scholar 

  13. Asada Y, Sumiyoshi A, Hayashi T, Suzumiya J, Kaketani K (1985) Immunohistochemistry of vascular lesion in thrombotic thrombocytopenic purpura, with special reference to factor VIII related antigen. Thromb Res 38:469–479

    CAS  PubMed  Google Scholar 

  14. Fujikawa K, Suzuki H, McMullen B, Chung D (2001) Purification of human von Willebrand factor-cleaving protease and its identification as a new member of the metalloproteinase family. Blood 98:1662–1666

    CAS  PubMed  Google Scholar 

  15. Levy GG, Nichols WC, Lian EC, Foroud T, McClintick JN, McGee BM, Yang AY, Siemieniak DR, Stark KR, Gruppo R, Sarode R, Shurin SB, Chandrasekaran V, Stabler SP, Sabio H, Bouhassira EE, Upshaw JD Jr, Ginsburg D, Tsai HM (2001) Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature 413:488–494

    CAS  PubMed  Google Scholar 

  16. Zheng X, Chung D, Takayama TK, Majerus EM, Sadler JE, Fujikawa K (2001) Structure of von Willebrand factor-cleaving protease (ADAMTS13), a metalloprotease involved in thrombotic thrombocytopenic purpura. J Biol Chem 276:41059–41063

    CAS  PubMed  Google Scholar 

  17. Veyradier A, Meyer D (2005) Thrombotic thrombocytopenic purpura and its diagnosis. J Thromb Haemost 3:2420–2427

    CAS  PubMed  Google Scholar 

  18. Sadler JE (2006) Thrombotic thrombocytopenic purpura: a moving target. Hematology Am Soc Hematol Educ Program 415–420

    Google Scholar 

  19. Kinoshita S, Yoshioka A, Park YD, Ishizashi H, Konno M, Funato M, Matsui T, Titani K, Yagi H, Matsumoto M, Fujimura Y (2001) Upshaw-Schulman syndrome revisited: a concept of congenital thrombotic thrombocytopenic purpura. Int J Hematol 74:101–108

    CAS  PubMed  Google Scholar 

  20. Schulman I, Pierce M, Lukens A, Currimbhoy Z (1960) Studies on thrombopoiesis. I. A factor in normal human plasma required for platelet production; chronic thrombocytopenia due to its deficiency. Blood 16:943–957

    CAS  PubMed  Google Scholar 

  21. Upshaw JD Jr (1978) Congenital deficiency of a factor in normal plasma that reverses microangiopathic hemolysis and thrombocytopenia. N Engl J Med 298:1350–1352

    PubMed  Google Scholar 

  22. Sasahara Y, Kumaki S, Ohashi Y, Minegishi M, Kano H, Bessho F, Tsuchiya S (2001) Deficient activity of von Willebrand factor-cleaving protease in patients with Upshaw-Schulman syndrome. Int J Hematol 74:109–114

    CAS  PubMed  Google Scholar 

  23. Kentouche K, Budde U, Furlan M, Scharfe V, Schneppenheim R, Zintl F (2002) Remission of thrombotic thrombocytopenic purpura in a patient with compound heterozygous deficiency of von Willebrand factor-cleaving protease by infusion of solvent/detergent plasma. Acta Paediatr 91:1056–1059

    CAS  PubMed  Google Scholar 

  24. Kokame K, Matsumoto M, Soejima K, Yagi H, Ishizashi H, Funato M, Tamai H, Konno M, Kamide K, Kawano Y, Miyata T, Fujimura Y (2002) Mutations and common polymorphisms in ADAMTS13 gene responsible for von Willebrand factor-cleaving protease activity. Proc Natl Acad Sci U S A 99:11902–11907

    CAS  PubMed  PubMed Central  Google Scholar 

  25. Antoine G, Zimmermann K, Plaimauer B, Grillowitzer M, Studt JD, Lammle B, Scheiflinger F (2003) ADAMTS13 gene defects in two brothers with constitutional thrombotic thrombocytopenic purpura and normalization of von Willebrand factor-cleaving protease activity by recombinant human ADAMTS13. Br J Haematol 120:821–824

    CAS  PubMed  Google Scholar 

  26. Assink K, Schiphorst R, Allford S, Karpman D, Etzioni A, Brichard B, van de Kar N, Monnens L, van den Heuvel L (2003) Mutation analysis and clinical implications of von Willebrand factor-cleaving protease deficiency. Kidney Int 63:1995–1999

    CAS  PubMed  Google Scholar 

  27. Bestetti G, Stellari A, Lattuada A, Corbellino M, Parravicini C, Calzarossa C, Cenzuales S, Moroni M, Galli M, Rossi E (2003) ADAMTS 13 genotype and vWF protease activity in an Italian family with TTP. Thromb Haemost 90:955–956

    CAS  PubMed  Google Scholar 

  28. Savasan S, Lee SK, Ginsburg D, Tsai HM (2003) ADAMTS13 gene mutation in congenital thrombotic thrombocytopenic purpura with previously reported normal VWF cleaving protease activity. Blood 101:4449–4451

    CAS  PubMed  Google Scholar 

  29. Schneppenheim R, Budde U, Oyen F, Angerhaus D, Aumann V, Drewke E, Hassenpflug W, Haberle J, Kentouche K, Kohne E, Kurnik K, Mueller-Wiefel D, Obser T, Santer R, Sykora KW (2003) Von Willebrand factor cleaving protease and ADAMTS 13 mutations in childhood TTP. Blood 101:1845–1850

    CAS  PubMed  Google Scholar 

  30. Kokame K, Miyata T (2004) Genetic defects leading to hereditary thrombotic thrombocytopenic purpura. Semin Hematol 41:34–40

    CAS  PubMed  Google Scholar 

  31. Licht C, Stapenhorst L, Simon T, Budde U, Schneppenheim R, Hoppe B (2004) Two novel ADAMTS13 gene mutations in thrombotic thrombocytopenic purpura/hemolytic-uremic syndrome (TTP/HUS). Kidney Int 66:955–958

    CAS  PubMed  Google Scholar 

  32. Matsumoto M, Kokame K, Soejima K, Miura M, Hayashi S, Fujii Y, Iwai A, Ito E, Tsuji Y, Takeda-Shitaka M, Iwadate M, Umeyama H, Yagi H, Ishizashi H, Banno F, Nakagaki T, Miyata T, Fujimura Y (2004) Molecular characterization of ADAMTS13 gene mutations in Japanese patients with Upshaw-Schulman syndrome. Blood 103:1305–1310

    CAS  PubMed  Google Scholar 

  33. Schneppenheim R, Budde U, Hassenpflug W, Obser T (2004) Severe ADAMTS-13 deficiency in childhood. Semin Hematol 41:83–89

    CAS  PubMed  Google Scholar 

  34. Uchida T, Wada H, Mizutani M, Iwashita M, Ishihara H, Shibano T, Suzuki M, Matsubara Y, Soejima K, Matsumoto M, Fujimura Y, Ikeda Y, Murata M (2004) Identification of novel mutations in ADAMTS13 in an adult patient with congenital thrombotic thrombocytopenic purpura. Blood 104:2081–2083

    CAS  PubMed  Google Scholar 

  35. Veyradier A, Lavergne JM, Ribba AS, Obert B, Loirat C, Meyer D, Girma JP (2004) Ten candidate ADAMTS13 mutations in six French families with congenital thrombotic thrombocytopenic purpura (Upshaw-Schulman syndrome). J Thromb Haemost 2:424–429

    CAS  PubMed  Google Scholar 

  36. Lowe EJ, Werner EJ (2005) Thrombotic thrombocytopenic purpura and hemolytic uremic syndrome in children and adolescents. Semin Thromb Hemost 31:717–730

    PubMed  Google Scholar 

  37. Loirat C, Veyradier A, Girma JP, Ribba AS, Meyer D (2006) Thrombotic thrombocytopenic purpura associated with von Willebrand factor-cleaving protease (ADAMTS13) deficiency in children. Semin Thromb Hemost 32:90–97

    CAS  PubMed  Google Scholar 

  38. Peyvandi F, Lavoretano S, Palla R, Valsecchi C, Merati G, De Cristofaro R, Rossi E, Mannuccio Mannucci P (2006) Mechanisms of the interaction between two ADAMTS13 gene mutations leading to severe deficiency of enzymatic activity. Hum Mutat 27:330–336

    CAS  PubMed  Google Scholar 

  39. Shibagaki Y, Matsumoto M, Kokame K, Ohba S, Miyata T, Fujimura Y, Fujita T (2006) Novel compound heterozygote mutations (H234Q/R1206X) of the ADAMTS13 gene in an adult patient with Upshaw-Schulman syndrome showing predominant episodes of repeated acute renal failure. Nephrol Dial Transplant 21:1289–1292

    CAS  PubMed  Google Scholar 

  40. Tao Z, Anthony K, Peng Y, Choi H, Nolasco L, Rice L, Moake JL, Dong JF (2006) Novel ADAMTS-13 mutations in an adult with delayed onset thrombotic thrombocytopenic purpura. J Thromb Haemost 4:1931–1935

    CAS  PubMed  Google Scholar 

  41. Motto D, Levy G, Mcgee B, Tsai HM, Ginsburg D (2003) ADAMTS13 mutations identified in familial TTP patients result in loss of VWF-cleaving protease activity. J Thromb Haemost 1(Suppl):OC115

    Google Scholar 

  42. Pimanda JE, Ganderton T, Maekawa A, Yap CL, Lawler J, Kershaw G, Chesterman CN, Hogg PJ (2004) Role of thrombospondin-1 in control of von Willebrand factor multimer size in mice. J Biol Chem 279:21439–21448

    CAS  PubMed  Google Scholar 

  43. Plaimauer B, Fuhrmann J, Mohr G, Wernhart W, Bruno K, Ferrari S, Konetschny C, Antoine G, Rieger M, Scheiflinger F (2006) Modulation of ADAMTS13 secretion and specific activity by a combination of common amino acid polymorphisms and a missense mutation. Blood 107:118–125

    CAS  PubMed  Google Scholar 

  44. Donadelli R, Banterla F, Galbusera M, Capoferri C, Bucchioni S, Gastoldi S, Nosari S, Monteferrante G, Ruggeri ZM, Bresin E, Scheiflinger F, Rossi E, Martinez C, Coppo R, Remuzzi G, Noris M (2006) In-vitro and in-vivo consequences of mutations in the von Willebrand factor cleaving protease ADAMTS 13 in thrombotic thrombocytopenic purpura. Thromb Haemost 96:454–564

    CAS  PubMed  Google Scholar 

  45. Manea M, Kristoffersson A, Tsai HM, Zhou W, Winqvist I, Oldaeus G, Billström R, Björk P, Holmberg L, Karpman D (2007) ADAMTS 13 phenotype in plasma from normal individuals and patients with thrombotic thrombocytopenic purpura. Eur J Pediatr 166:249–257

    CAS  PubMed  Google Scholar 

  46. Rieger M, Mannucci PM, Kremer Hovinga JA, Herzog A, Gerstenbauer G, Konetschny C, Zimmermann K, Scharrer I, Peyvandi F, Galbusera M, Remuzzi G, Böhm M, Plaimauer B, Lämmle B, Scheiflinger F (2005) ADAMTS13 autoantibodies in patients with thrombotic microangiopathies and other immunomediated diseases. Blood 106:1262–1267

    CAS  PubMed  Google Scholar 

  47. Ashida A, Nakamura H, Yoden A, Tamai H, Ishizashi H, Yagi H, Matsumoto M, Fujimura Y (2002) Successful treatment of a young infant who developed high-titer inhibitors against VWF-cleaving protease (ADAMTS-13): important discrimination from Upshaw-Schulman syndrome. Am J Hematol 71:318–322

    PubMed  Google Scholar 

  48. Robson WL, Tsai HM (2002) Thrombotic thrombocytopenic purpura attributable to von Willebrand factor-cleaving protease inhibitor in an 8-year-old boy. Pediatrics 109:322–325

    PubMed  Google Scholar 

  49. Horton TM, Stone JD, Yee D, Dreyer Z, Moake JL, Mahoney DH (2003) Case series of thrombotic thrombocytopenic purpura in children and adolescents. J Pediatr Hematol Oncol 25:336–339

    PubMed  Google Scholar 

  50. Curtillet C, Poullin P, Doré E, Fossat C, Lefevre P, Michel G (2006) Paediatric case report of an acquired autoimmune thrombotic thrombocytopenic purpura. Arch Pediatr 13:1521–1524

    CAS  PubMed  Google Scholar 

  51. Veyradier A, Girma JP (2004) Assays of ADAMTS13 activity. Semin Hematol 41:41–47

    CAS  PubMed  Google Scholar 

  52. Kokame K, Matsumoto M, Fujimura Y, Miyata T (2004) VWF73, a region from D1596 to R1668 of von Willebrand factor, provides a minimal substrate for ADAMTS-13. Blood 103:607–612

    CAS  PubMed  Google Scholar 

  53. Kokame K, Nobe Y, Kokubo Y, Okayama A, Miyata T (2005) FRETS-VWF73, a first fluorogenic substrate for ADAMTS13 assay. Br J Haematol 129:93–100

    CAS  PubMed  Google Scholar 

  54. Hommais A, Rayes J, Houllier A, Obert B, Legendre P, Veyradier A, Girma JP, Ribba AS (2007) Molecular characterization of four ADAMTS13 mutations responsible for congenital thrombotic thrombocytopenic purpura. Thromb Haemost 98:593–599

    CAS  PubMed  Google Scholar 

  55. Zhou W, Bouhassira EE, Tsai HM (2007) An IAP retrotransposon in the mouse ADAMTS13 gene creates ADAMTS13 variant proteins that are less effective in cleaving von Willebrand factor multimers. Blood 110:886–893

    CAS  PubMed  PubMed Central  Google Scholar 

  56. Schmugge M, Dunn MS, Amankwah KS, Blanchette VS, Freedman J, Rand ML (2004) The activity of the von Willebrand factor cleaving protease ADAMTS-13 in newborn infants. J Thromb Haemost 2:228–233

    CAS  PubMed  Google Scholar 

  57. Ferrari S, Scheiflinger F, Rieger M, Mudde G, Wolf M, Coppo P, Girma JP, Azoulay E, Brun-Buisson C, Fakhouri F, Mira JP, Oksenhendler E, Poullin P, Rondeau E, Schleinitz N, Schlemmer B, Teboul JL, Vanhille P, Vernant JP, Meyer D, Veyradier A (2007) Prognostic value of anti-ADAMTS13 antibodies features (Ig isotype, titer and inhibitory effect) in a cohort of 35 adult French patients undergoing a first episode of thrombotic microangiopathy with an undetectable ADAMTS13 activity. Blood 109:2815–2822

    CAS  PubMed  Google Scholar 

  58. Deschênes G, Veyradier A, Cloarec S, Benoit S, Desbois I, Gruel Y, Nivet H (2002) Plasma therapy in von Willebrand factor protease deficiency. Pediatr Nephrol 17:867–870

    PubMed  Google Scholar 

  59. Veyradier A, Obert B, Haddad E, Cloarec S, Nivet H, Foulard M, Lesure F, Delattre P, Lakhdari M, Meyer D, Girma JP, Loirat C (2003) Severe deficiency of the specific von Willebrand factor-cleaving protease (ADAMTS 13) activity in a subgroup of children with atypical hemolytic uremic syndrome. J Pediatr 14:310–317

    Google Scholar 

  60. Jamshed S, Kouides P, Sham R, Cramer S (2007) Pathology of thrombotic thrombocytopenic purpura in the placenta, with emphasis on the snowman sign. Pediatr Dev Pathol 10:455–462

    PubMed  Google Scholar 

  61. Furlan M, Lammle B (2001) Aetiology and pathogenesis of thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome: the role of von Willebrand factor-cleaving protease. Best Pract Res Clin Haematol 14:437–454

    CAS  PubMed  Google Scholar 

  62. Noris M, Bucchioni S, Galbusera M, Donadelli R, Bresin E, Castelletti F, Caprioli J, Brioschi S, Scheiflinger F, Remuzzi G (2005) Complement factor H mutation in familial thrombotic thrombocytopenic purpura with ADAMTS 13 deficiency and renal involvement. J Am Soc Nephrol 16:1177–1183

    CAS  PubMed  Google Scholar 

  63. Furlan M, Robles R, Solenthaler M, Wassmer M, Sandoz P, Lämmle B (1997) Deficient activity of von Willebrand factor-cleaving protease in chronic relapsing thrombotic thrombocytopenic purpura. Blood 89:3097–3103

    CAS  PubMed  Google Scholar 

  64. Zheng XL, Sadler JE (2008) Pathogenesis of thrombotic microangiopathies. Annu Rev Pathol 3:249–277

    CAS  PubMed  PubMed Central  Google Scholar 

  65. Motto DG, Chauhan AK, Zhu G, Homeister J, Lamb CB, Desch KC, Zhang W, Tsai HM, Wagner DD, Ginsburg D (2005) Shigatoxin triggers thrombotic thrombocytopenic purpura in genetically susceptible ADAMTS 13-deficient mice. J Clin Invest 115:2752–2761

    CAS  PubMed  PubMed Central  Google Scholar 

  66. Chak WK, Lam DS, Lo WH, Hui CM, Wong SN (2000) Thrombotic thrombocytopenic purpura as a rare complication in childhood systemic lupus erythematosus: case report and literature review. Hong Kong Med J 9:363–368

    Google Scholar 

  67. Coppo P, Bengoufa D, Veyradier A, Wolf M, Bussel A, Millot GA, Malot S, Heshmati F, Mira JP, Boulanger E, Galicier L, Durey-Dragon MA, Fremeaux-Bacchi V, Ramakers M, Pruna A, Bordessoule D, Gouilleux V, Scrobohaci ML, Vernant JP, Moreau D, Azoulay E, Schlemmer B, Guillevin L, Lassoued K (2004) Severe ADAMTS 13 deficiency in adult idiopathic thrombotic microangiopathies defines a subset of patients characterized by various autoimmune manifestations, lower platelet count, and mild renal involvement. Medicine (Baltimore) 83:233–244

    CAS  Google Scholar 

  68. Coppo P, Veyradier A, Monge M (2006) Acquired idiopathic thrombotic thrombocytopenic purpura: arguments for an autoimmune disease. Presse Med 35:1876–1886

    PubMed  Google Scholar 

  69. George JN, Vesely SK, Terrell DR (2004) The Oklahoma thrombotic thrombocytopenic purpura-hemolytic uremic syndrome (TTP-HUS) registry: a community perspective of patients with clinically diagnosed TTP-HUS. Semin Hematol 41:60–67

    PubMed  Google Scholar 

  70. Coppo P, Wolf M, Veyradier A, Bussel A, Malot S, Millot GA, Daubin C, Bordessoule D, Pene F, Mira JP, Heshmati F, Maury E, Guidet B, Boulanger E, Galicier L, Parquet N, Vernant JP, Rondeau E, Azoulay E, Schlemmer B (2006) Prognostic value of inhibitory anti-ADAMTS 13 antibodies in adult-acquired thrombotic thrombocytopenic purpura. Br J Haematol 132:66–74

    CAS  PubMed  Google Scholar 

  71. Rock GA (2000) Management of thrombotic thrombocytopenic purpura. Br J Haematol 109:496–507

    CAS  PubMed  Google Scholar 

  72. Fontana S, Hovinga JA, Studt JD, Alberio L, Lammle B, Taleghani BM (2004) Plasma therapy in thrombotic thrombocytopenic purpura: review of the literature and the Bern experience in a subgroup of patients with severe acquired ADAMTS-13 deficiency. Semin Hematol 41:48–59

    CAS  PubMed  Google Scholar 

  73. Furlan M, Robles R, Morselli B, Sandoz P, Lammle B (1999) Recovery and half-life of von Willebrand factor-cleaving protease after plasma therapy in patients with thrombotic thrombocytopenic purpura. Thromb Haemost 81:8–13

    CAS  PubMed  Google Scholar 

  74. Rock G, Yousef H, Neurath D, Lu M (2006) ADAMTS-13 levels in fresh, stored, and solvent detergent treated plasma. Transf Apher Sci 35:235–238

    CAS  Google Scholar 

  75. Heger A, Kannicht C, Römisch J, Svae TE (2007) Normal levels of ADAMTS 13 and factor H are present in the pharmaceutically licensed plasma for transfusion (Octaplas) and in the universally applicable plasma (Uniplas) in development. Vox Sang 92:206–212

    CAS  PubMed  Google Scholar 

  76. Scott EA, Puca KE, Pietz BC, Duchateau BK, Friedman KD (2007) Comparison and stability of ADAMTS 13 activity in therapeutic plasma products. Transfusion 47:120–125

    CAS  PubMed  Google Scholar 

  77. Snider CE, Moore JC, Warkentin TE, Finch CN, Hayward CP, Kelton JG (2004) Dissociation between the level of von Willebrand factor-cleaving protease activity and disease in a patient with congenital thrombotic thrombocytopenic purpura. Am J Hematol 77:387–390

    PubMed  Google Scholar 

  78. George JN (2007) Evaluation and management of patients with thrombotic thrombocytopenic purpura. J Intensive Care Med 22:82–91

    PubMed  Google Scholar 

  79. Cataland SR, Jin M, Lin S, Kennedy MS, Kraut EH, George JN, Wu HM (2007) Cyclosporin and plasma exchange in thrombotic thrombocytopenic purpura: long-term follow-up with serial analysis of ADAMTS 13 activity. Br J Haematol 139:486–493

    CAS  PubMed  Google Scholar 

  80. Fakhouri F, Vernant JP, Veyradier A, Wolf M, Kaplanski G, Binaut R, Rieger M, Scheiflinger F, Poullin P, Deroure B, Delarue R, Lesavre P, Vanhille P, Hermine O, Remuzzi G, Grünfeld JP (2005) Efficiency of curative and prophylactic treatment with rituximab in ADAMTS 13-deficient thrombotic thrombocytopenic purpura: a study of 11 cases. Blood 106:1932–1937

    CAS  PubMed  Google Scholar 

  81. George JN, Woodson RD, Kiss JE, Kojouri K, Vesely SK (2006) Rituximab therapy for thrombotic thrombocytopenic purpura: a proposed study of the Transfusion Medicine/Hemostasis Clinical Trials Network with a systematic review of rituximab therapy for immune-mediated disorders. J Clin Apher 21:49–56

    PubMed  Google Scholar 

  82. Heidel F, Lipka DB, von Auer C, Huber C, Scharrer I, Hess G (2007) Addition of rituximab to standard therapy improves response rate and progression-free survival in relapsed or refractory thrombotic thrombocytopenic purpura and autoimmune haemolytic anaemia. Thromb Haemost 97:228–233

    CAS  PubMed  Google Scholar 

  83. Rüfer A, Brodmann D, Gregor M, Kremer Hovinga JA, Lämmle B, Wuillemin WA (2007) Rituximab for acute plasma-refractory thrombotic thrombocytopenic purpura. A case report and concise review of the literature. Swiss Med Wkly 137:518–524

    PubMed  Google Scholar 

  84. Brodin-Sartorius A, Guebre-Egziabher F, Fouque D, Cozon G, Villar E, Laville M, Juillard L (2006) Recurrent idiopathic thrombotic thrombocytopenic purpura: a role for vaccination in disease relapse? Am J Kidney Dis 48:e31–e34

    PubMed  Google Scholar 

  85. Reiter RA, Knobl P, Varadi K, Turecek PL (2003) Changes in von Willebrand factor-cleaving protease (ADAMTS 13) activity after infusion of desmopressin. Blood 101:946–948

    CAS  PubMed  Google Scholar 

  86. Mannucci PM, Capoferri C, Canciani MT (2004) Plasma levels of von Willebrand factor regulate ADAMTS 13, its major cleaving protease. Br J Haematol 126:213–218

    CAS  PubMed  Google Scholar 

  87. Hara T, Kitano A, Kajiwara T, Kondo T, Sakai K, Hamasaki Y (1986) Factor VIII concentrate-responsive thrombocytopenia, haemolytic anemia, and nephropathy. Evidence that factor VIII: von Willebrand factor is involved in its pathogenesis. Am J Pediatr Hematol Oncol 8:324–328

    CAS  PubMed  Google Scholar 

  88. Veyradier A, Meyer D, Loirat C (2006) Desmopressin, an unexpected link between nocturnal enuresis and inherited thrombotic thrombocytopenic purpura (Upshaw-Schulman syndrome). J Thromb Haemost 4:700–701

    CAS  PubMed  Google Scholar 

  89. Jalanko H, Peltonen S, Koskinen A, Puntila J, Isoniemi H, Holmberg C, Pinomäki A, Armstrong E, Koivusalo A, Tukiainen E, Mäkisalo H, Saland J, Remuzzi G, de Cordoba S, Lassila R, Meri S, Jokiranta TS (2008) Successful liver-kidney transplantation in two children with aHUS caused by a mutation in complement factor H. Am J Transplant 8:216–221

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Service de Néphrologie, Hôpital Robert Debré, Assistance Publique-Hôpitaux de Paris, Université Paris VII, 48 Boulevard Sérurier, 75019, Paris, France

    Chantal Loirat

  2. Centre National de Référence des Microangiopathies Thrombotiques de l’adulte et de l’enfant, Paris, France

    Chantal Loirat, Paul Coppo & Agnès Veyradier

  3. Inserm U770, Université Paris XI, Le Kremlin Bicêtre, France

    Jean-Pierre Girma, Céline Desconclois & Agnès Veyradier

  4. Service d’Hématologie biologique, Hôpital Antoine Béclère, Assistance Publique-Hôpitaux de Paris, Clamart, France

    Céline Desconclois & Agnès Veyradier

  5. Service d’Hématologie clinique, Hôpital Saint Antoine, Assistance Publique-Hôpitaux de Paris, Université Paris VI, Paris, France

    Paul Coppo

Authors
  1. Chantal Loirat
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jean-Pierre Girma
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Céline Desconclois
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Paul Coppo
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Agnès Veyradier
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Chantal Loirat.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Loirat, C., Girma, JP., Desconclois, C. et al. Thrombotic thrombocytopenic purpura related to severe ADAMTS13 deficiency in children. Pediatr Nephrol 24, 19–29 (2009). https://doi.org/10.1007/s00467-008-0863-5

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00467-008-0863-5

Keywords

Search

Navigation